ZyVersa Therapeutics (ZVSA)
OTHER OTC:ZVSA
Top Page
ZyVersa Therapeutics
(OTC:ZVSA)
Select Model
Select Model
Rating:41Neutral
Price Target:
$0.19
▲(46.92% Upside)
Action:ReiteratedDate:04/01/26
The score is driven primarily by weak financial performance—no revenue, accelerating losses, rising cash burn, and negative equity in 2025—implying elevated funding and dilution risk. Technicals also lean bearish with negative MACD and the stock below key short-term averages, while valuation is constrained by negative earnings and no dividend support.
Positive Factors
Focused Clinical-Stage Pipeline
ZyVersa’s concentrated R&D focus on renal and inflammatory disorders (FSGS, VAR 200 antibody, IC 100 small molecule) creates a clear strategic roadmap. Specialization in high-unmet-need indications can produce durable value if clinical proof-of-concept is achieved and preserves resource allocation efficiency.
Negative Factors
Pre-Revenue with Accelerating Losses
Being pre-revenue leaves the company entirely reliant on external capital while operating losses worsened sharply in 2025. This persistent negative operating performance increases the probability of repeated financings and raises execution risk for multi-year clinical programs without an internal revenue cushion.
Read all positive and negative factors
Positive Factors
Negative Factors
Focused Clinical-Stage Pipeline
ZyVersa’s concentrated R&D focus on renal and inflammatory disorders (FSGS, VAR 200 antibody, IC 100 small molecule) creates a clear strategic roadmap. Specialization in high-unmet-need indications can produce durable value if clinical proof-of-concept is achieved and preserves resource allocation efficiency.
Read all positive factors
ZyVersa Therapeutics (ZVSA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.62M
Dividend YieldN/A
Average Volume (3M)51.59K
Price to Earnings (P/E)―
Beta (1Y)1.34
Revenue GrowthN/A
EPS Growth88.30%
CountryUS
Employees7
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.43
Shares Outstanding8,095,921
10 Day Avg. Volume65,792
30 Day Avg. Volume51,592
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-0.06
Price to Sales (P/S)0.00
P/FCF Ratio-0.16
Enterprise Value/Market Cap-61.86
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.17
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-65.8
Revenue Forecast (FY)N/A
ZyVersa Therapeutics Business Overview & Revenue Model
Company Description
ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. It engages in the development of VAR 200, a cholesterol efflux mediator to treat foc...
How the Company Makes Money
null...
ZyVersa Therapeutics Financial Statement Overview
Summary
Income Statement
6
Very Negative
Balance Sheet
8
Very Negative
Cash Flow
10
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | -6.93K | -10.40K | -10.40K | -10.40K |
| EBITDA | -25.49B | -9.14B | -107.74M | -14.43M | -7.25M |
| Net Income | -24.95B | -9.41B | -98.30M | -14.05M | -8.08M |
Balance Sheet | |||||
| Total Assets | 347.90M | 20.60M | 22.11M | 118.51M | 1.13M |
| Cash, Cash Equivalents and Short-Term Investments | 101.78M | 1.53M | 3.14M | 5.90M | 328.58K |
| Total Debt | 0.00 | 0.00 | 8.66K | 108.76K | 9.15M |
| Total Liabilities | 12.73B | 12.08M | 11.04M | 18.51M | 13.63M |
| Stockholders Equity | -12.39B | 8.52M | 11.07M | 99.99M | -12.50M |
Cash Flow | |||||
| Free Cash Flow | -5.11B | -7.56M | -8.72M | -1.49M | -5.08M |
| Operating Cash Flow | -5.11B | -7.56M | -8.72M | -4.89M | -5.08M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financing Cash Flow | 3.69B | 5.95M | 5.96M | 1.87M | 5.23M |
ZyVersa Therapeutics Technical Analysis
Negative
0.13
Price Trends
0.22
Negative
0.18
Positive
0.22
Negative
Market Momentum
>-0.01
Positive
41.98
Neutral
38.46
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ZVSA, the sentiment is Negative. The current price of 0.13 is below the 20-day moving average (MA) of 0.23, below the 50-day MA of 0.22, and below the 200-day MA of 0.22, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 41.98 is Neutral, neither overbought nor oversold. The STOCH value of 38.46 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ZVSA.
ZyVersa Therapeutics Risk Analysis
ZyVersa Therapeutics disclosed 86 risk factors in its most recent earnings report. ZyVersa Therapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
ZyVersa Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
ZVSA
ZyVersa Therapeutics
0.20
-0.42
-67.59%
SCNI
Scinai Immunotherapeutics
0.60
-1.93
-76.28%
ADTX
Aditxt
0.79
-4,275.13
-99.98%
CERO
CERo Therapeutics Holdings
0.03
-14.27
-99.76%
PBM
Psyence Biomedical
2.47
-20.54
-89.27%
CDT
CDT Equity
3.95
-1,933.15
-99.80%
ZyVersa Therapeutics Corporate Events
Private Placements and Financing
ZyVersa Therapeutics Announces $1 Million Convertible Note Financing
Neutral
Mar 5, 2026
On February 27, 2026, ZyVersa Therapeutics entered into a Securities Purchase Agreement with accredited investors for a $1 million private placement of convertible promissory notes and accompanying Series A-4 common stock purchase warrants. The no...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.